$PSTV News

Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript

Plus Therapeutics Announces Name Change To Cerenome, With Nasdaq Trading Under Symbol 'CNSY,' Effective August 3; Reaffirms FY26 Milestone And Commercial Guidance

Plus Therapeutics to Provide Business Update Call on June 30, 2026

Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $57

Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American Pathologists

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid Assay

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS Oncology

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Plus Therapeutics Q1 EPS $(1.05) Misses $(0.85) Estimate, Sales $1.028M Beat $974.000K Estimate

Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Plus Therapeutics Presents Plenary Session Reviewing Key Clinical And Translational Data, Including Phase 1 ReSPECT-LM Trial Of REYOBIQ At 2026 AANS Annual Scientific Meeting

OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Plus Therapeutics Subsidiary Gets Enrolled In Medicare Program, Receives Provider Transaction Access Number From Centers For Medicare & Medicaid Services